The following government grants in the FederalGrants.com database contain the term housing in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| Methodology and Measurement in the Behavioral and Social Sciences (R21) Clinical Trials Optional |
93.173, 93.213, 93.273, 93.313, 93.399, 93.866, 93.867 |
PAR-18-378 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R21)- Clinical Trials Not Allowed |
93.121, 93.173, 93.399 |
PA-18-406 |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 - No Independent Clinical Trials) |
93.113, 93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.398, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.855, 93.859, 93.865, 93.866, 93.867 |
PA-18-373 |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required) |
93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.398, 93.837, 93.838, 93.839, 93.840, 93.853, 93.865, 93.866, 93.867 |
PA-18-372 |
| A Family-Centered Self-Management of Chronic Conditions (R01 Clinical Trial Optional) |
93.361 |
PA-18-383 |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) |
93.242 |
PAR-18-268 |
| National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19 Clinical Trial Optional) |
93.242, 93.273, 93.279 |
PAR-18-231 |
| Independent Scientist Award (Parent K02 - Independent Clinical Trials Not Allowed) |
93.113, 93.121, 93.273, 93.279, 93.866 |
PA-18-371 |
| Independent Scientist Award (Parent K02 - Independent Clinical Trial Required) |
93.121, 93.273, 93.279, 93.853, 93.866 |
PA-18-370 |
| Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21- Clinical Trial Required) |
93.847 |
PA-18-405 |
| Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) |
93.279 |
PAR-18-219 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional) |
93.279 |
PAR-18-218 |
| Limited Competition: Exploratory CTSA Collaborative Innovation Awards (R21 Clinical Trial Optional) |
93.350 |
PAR-18-245 |
| Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01 Clinical Trial Optional) |
93.350 |
PAR-18-244 |
| Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required) |
93.242 |
PAR-18-232 |
| National Cooperative Drug/Device Discovery/Development Groups (U01 Clinical Trial Optional) |
93.242, 93.273, 93.279 |
PAR-18-230 |
| Human-Animal Interaction (HAI) Research (R01 Clinical Trial Optional) |
93.865 |
PAR-18-213 |
| Research To Address Sleep Disorders in the Context of Medical Rehabilitation (R01 Clinical Trial Optional) |
93.361, 93.865 |
PAR-18-212 |
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) |
93.865 |
PAR-18-211 |
| Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required) |
93.242 |
PAR-18-233 |
| NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) |
93.393, 93.394, 93.395, 93.396, 93.397, 93.399 |
PAR-18-021 |
| Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01 Clinical Trial Optional) |
93.847 |
RFA-DK-17-036 |
| The Role of the Microbiome in the Developmental Origins of Health and Disease (DOHaD) (R01 Clinical Trial Not Allowed) |
93.113 |
RFA-ES-18-005 |
| Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R34 Clinical Trial Required) |
93.847 |
PAR-18-107 |
| Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R18 Clinical Trial Required) |
93.847 |
PAR-18-106 |
| Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional) |
93.847 |
PAR-18-105 |
| Mentored Research Scientist Development Award (Parent K01 - Clinical Trial Required) |
93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.361, 93.837, 93.838, 93.839, 93.840, 93.846, 93.865, 93.866 |
PA-18-363 |
| Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) |
93.077 |
RFA-OD-18-001 |
| NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required) |
93.398 |
PAR-18-367 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) |
93.394 |
RFA-CA-18-005 |
| Mentored Research Scientist Development Award (Parent K01 -Independent Clinical Trial Not Allowed) |
93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.351, 93.361, 93.837, 93.838, 93.839, 93.840, 93.855, 93.865, 93.866 |
PA-18-369 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed) |
93.394 |
RFA-CA-18-004 |
| Tobacco Regulatory Science (R21 Clinical Trial Optional) |
93.077 |
RFA-OD-18-003 |
| NCI Transition Career Development Award to Promote Diversity (K22 - No Clinical Trials) |
93.398 |
PAR-18-366 |
| Tobacco Regulatory Science (R01 Clinical Trial Optional) |
93.077 |
RFA-OD-18-002 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) |
93.394 |
RFA-CA-18-003 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed) |
93.394 |
RFA-CA-18-002 |
| Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed) |
93.847 |
PA-18-412 |
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01) |
93.398 |
PAR-18-364 |
| Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) |
93.273, 93.279, 93.399 |
PAR-18-086 |
Search Results 1601-1640 of 12343
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 [Next] |
